Lakefront Biotherapeutics (LKFT) Change in Account Payables (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Change in Account Payables for 5 consecutive years, with -$69.7 million the latest figure, recorded in Q2 2020.

• Quarterly Change in Account Payables fell 284.82% year-over-year to -$69.7 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was -$112.9 million (down 5614.22% YoY) and the FY2025 annual result came in at $38.5 million, up 163.29% from the prior year.
• Change in Account Payables eased to -$69.7 million in Q2 2020 per LKFT's latest filing, from $28.4 million in the prior quarter.
• Over the last five years, Change in Account Payables for LKFT reached as high as $7.6 billion in Q2 2017 and fell as low as -$7.6 billion in Q3 2017.
• A 5-year average of -$7.4 million and a median of $68240.5 in 2016 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2017 — Change in Account Payables surged 57439.84% — and 2018, when it tumbled 458.04%.
• Year by year, Change in Account Payables stood at -$13.3 million in 2016, then jumped by 220.1% to $16.0 million in 2017, then slumped by 458.04% to -$57.3 million in 2018, then sank by 196.24% to -$169.8 million in 2019, then surged by 58.95% to -$69.7 million in 2020.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$69.7 million, $28.4 million, and -$169.8 million for Q2 2020, Q1 2020, and Q4 2019 respectively.